KURE.US KraneShares MSCI All China Health Care Index ETF
- Total assets
- 115M
- Expense ratio
- 0.64%
- Dividend yield
- 4.22%
- 1-year return
- +0.55%
- Holdings
- 40
- Since
- 2018
Fund data as reported by the issuer, updated Nov 14, 2026. Total assets are in the fund's base currency.
What does KURE.US invest in?
- Mostly Non-US stocks (81.2%)
- Largest sector: Healthcare (100.4%)
- Largest region: Asia Emerging (78.0%)
- Top 3 holdings: 21.1% of the fund
Asset allocation
- Non-US stocks 81.2%
- US stocks 17.4%
- Cash 0.2%
Top holdings
- Innovent Biologics Inc 8.29%
- WuXi Biologics 7.25%
- WuXi AppTec Co Ltd 5.59%
- Jiangsu Hengrui Medicine Co Ltd 4.56%
- Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A 4.47%
KraneShares MSCI All China Health Care Index ETF performance
Sharpe ratio -0.02- This year
- +8.16%
- 1 year
- +0.55%
- 3 years
- +1.79%
- 5 years
- -8.30%
Volatility 20.5% over 1 year and 26.9% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
KURE.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About KraneShares MSCI All China Health Care Index ETF
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Full fund profileKraneShares MSCI All China Health Care Index ETF top holdings
47.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Innovent Biologics Inc 1801.HK | Healthcare | Hong Kong | 8.29% |
| WuXi Biologics 2269.HK | Healthcare | Hong Kong | 7.25% |
| WuXi AppTec Co Ltd 603259.SHG | Healthcare | China | 5.59% |
| Jiangsu Hengrui Medicine Co Ltd 600276.SHG | Healthcare | China | 4.56% |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A 300760.SHE | Healthcare | China | 4.47% |
| Sino Biopharmaceutical Ltd 1177.HK | Healthcare | Hong Kong | 4.03% |
| Akeso Inc 9926.HK | Healthcare | Hong Kong | 4.02% |
| CSPC Pharmaceutical Group Ltd 1093.HK | Healthcare | Hong Kong | 3.30% |
| WuXi AppTec Co Ltd H 2359.HK | Healthcare | Hong Kong | 3.14% |
| Hansoh Pharmaceutical Group Co Ltd 3692.HK | Healthcare | Hong Kong | 3.02% |
The 10 largest of 40 holdings.
KURE.US sector exposure
- Healthcare100.4%
- Consumer Defensive0.7%
Share of the stocks in the fund.
KURE.US regional exposure
- Asia Emerging78.0%
- North America17.6%
- Asia Developed3.9%
Share of the stocks in the fund.
Company size
Average market cap 17.1B- Mega cap12.6%
- Big cap65.3%
- Medium cap15.8%
- Small cap6.6%
KraneShares MSCI All China Health Care Index ETF fund profile
- Fund name
- KraneShares MSCI All China Health Care Index ETF
- Ticker
- KURE.US
- Exchange
- USA Stocks
- Issuer
- KraneShares
- Index tracked
- -
- Category
- Greater China Equity
- Inception date
- Jan 31, 2018
- Trading currency
- USD
- Expense ratio
- 0.64%
- Annual turnover
- 0.3%
About KraneShares MSCI All China Health Care Index ETF
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.